Prior to founding Inventages, Gunnar spent more than 28 years in a broad spectrum of functions within the pharmaceutical and biotech industry culminating as Senior Vice President and Global Head for Life Science deals at Bayer AG. While at Bayer, he oversaw venture investments in technology companies and collaborations representing some of the most significant deals between big pharma and biotechnology in the late 1990’s.

Wolfgang joined Nestlé in 1977 where he rapidly moved up through international positions of increasing responsibility culminating as Global CFO, position he successfully carried out for five years. While at Nestlé, where his career spans 30 years, he was instrumental in strengthening performance with revolutionary structural and financing projects.

Goetz worked for more than 14 years in leading positions for renowned pharmaceutical companies. He joined Inventages with a broad understanding of the international healthcare business; his search experience covers assignments for key corporate functions including Senior HR, Research and Development, Business Development, Marketing & Sales and Board Level functions.

Prior to joining Inventages, Ashok has had positions of significant corporate influence at Novartis, Serono, Baxter, Roche, Andersen Consulting and Rhone-Poulenc. With more than 25 years in life sciences, he has secured considerable experience in Corporate M&A, Business Development & Strategic Planning including general management.

Thomas is a physicist who spent 10 years in academia as a university professor of biophysics in Germany before becoming an entrepreneur who founded several life science technology start-ups in drug discovery in Germany and UK. He held positions as a partner of several VC/PE funds in Germany and Switzerland for more than 15 years and has considerable experience in science & technology assessment for medical-, bio- and nanotechnology and their potential for innovative commercial products and services.

At Inventages Thomas will contribute his outstanding experience as an investing partner of the new private equity fund.